Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study to Estimate the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2-low Status - the RetroBC-HER2L Study

NCT04807595 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04807595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04807595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study to Estimate the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2-low Status - the RetroBC-HER2L Study
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 28, 2021
Completion date
April 26, 2022
Enrollment
798 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer